Manufacturing of Pharmaceutical Proteins
Manufacturing of Pharmaceutical Proteins: From Technology to Economy, 3rd Edition eBooks & eLearning
Posted by yoyoloit at Dec. 23, 2021
Manufacturing of Pharmaceutical Proteins
by Behme, Stefan;
English | 2021 | ISBN: 3527349472 | 497 pages | True PDF | 9.65 MB
by Behme, Stefan;
English | 2021 | ISBN: 3527349472 | 497 pages | True PDF | 9.65 MB
Manufacturing of Pharmaceutical Proteins: From Technology to Economy [Repost] eBooks & eLearning
Posted by ChrisRedfield at Feb. 14, 2017
![Manufacturing of Pharmaceutical Proteins: From Technology to Economy [Repost]](https://pixhost.icu/avaxhome/50/53/00435350_medium.jpg)
Stefan Behme - Manufacturing of Pharmaceutical Proteins: From Technology to Economy
Published: 2009-02-17 | ISBN: 3527324445 | PDF | 404 pages | 5.43 MB
Manufacturing of Pharmaceutical Proteins: From Technology to Economy (2nd edition) [Repost] eBooks & eLearning
Posted by ChrisRedfield at June 29, 2019
![Manufacturing of Pharmaceutical Proteins: From Technology to Economy (2nd edition) [Repost]](https://pixhost.icu/avaxhome/8f/04/0069048f_medium.jpg)
Stefan Behme - Manufacturing of Pharmaceutical Proteins: From Technology to Economy (2nd edition)
Published: 2015-05-06 | ISBN: 3527337660 | PDF | 456 pages | 5.41 MB
Formulation and Process Development Strategies for Manufacturing Biopharmaceuticals eBooks & eLearning
Posted by insetes at Jan. 21, 2019
Formulation and Process Development Strategies for Manufacturing Biopharmaceuticals By
2010 | 950 Pages | ISBN: 0470118121 | PDF | 27 MB
2010 | 950 Pages | ISBN: 0470118121 | PDF | 27 MB
Handbook of Pharmaceutical Manufacturing Formulations, Vol. 2: Uncompressed Solid Products (2nd Edition) eBooks & eLearning
Posted by Jeembo at Oct. 26, 2018
Handbook of Pharmaceutical Manufacturing Formulations, Vol. 2: Uncompressed Solid Products (2nd Edition) by Sarfaraz K. Niazi
English | 2009 | ISBN: 1420081187 | 392 Pages | PDF | 7.3 MB
English | 2009 | ISBN: 1420081187 | 392 Pages | PDF | 7.3 MB
Providing methodologies that can serve as a reference point for new formulations, the second volume covers uncompressed solids, which include formulations of powders, capsules, powders ready for reconstitution, and other similar products.
Practical guide to hot-melt extrusion : continuous manufacturing and scale-up eBooks & eLearning
Posted by insetes at Nov. 22, 2021
Practical guide to hot-melt extrusion : continuous manufacturing and scale-up By Mohammed Maniruzzaman
2015 | 248 Pages | ISBN: 1910242659 | PDF | 4 MB
2015 | 248 Pages | ISBN: 1910242659 | PDF | 4 MB
Model-Based Control of Particulate Processes eBooks & eLearning
Posted by insetes at Dec. 30, 2018
Model-Based Control of Particulate Processes By Panagiotis D. Christofides (auth.)
2002 | 211 Pages | ISBN: 9048161487 | PDF | 8 MB
2002 | 211 Pages | ISBN: 9048161487 | PDF | 8 MB
The Challenge of CMC Regulatory Compliance for Biopharmaceuticals eBooks & eLearning
Posted by roxul at May 9, 2019
John Geigert, "The Challenge of CMC Regulatory Compliance for Biopharmaceuticals"
English | ISBN: 3030137538 | 2019 | 426 pages | PDF, EPUB | 24 MB
English | ISBN: 3030137538 | 2019 | 426 pages | PDF, EPUB | 24 MB
Pharmaceutical Dosage Forms: Parenteral Medications, 3rd Edition (3 Volume Set) eBooks & eLearning
Posted by arundhati at Sept. 4, 2018
Sandeep Nema, John D. Ludwig, "Pharmaceutical Dosage Forms: Parenteral Medications, 3rd Edition (3 Volume Set)"
2010 | ISBN-10: 1420086537 | 500 pages | PDF | 8 MB
2010 | ISBN-10: 1420086537 | 500 pages | PDF | 8 MB
The Challenge of CMC Regulatory Compliance for Biopharmaceuticals, Third Edition (Repost) eBooks & eLearning
Posted by AvaxGenius at Aug. 5, 2019
The Challenge of CMC Regulatory Compliance for Biopharmaceuticals by John Geigert
English | PDF,EPUB | 2019 | 446 Pages | ISBN : 3030137538 | 24.33 MB
Biopharmaceuticals (i.e., biological medicines sourced from genetically-engineered living systems) for treatment of human diseases have become a significant percentage of the pharmaceutical industry. And not just the recombinant DNA-derived proteins and monoclonal antibodies (both from the innovators and biosimilars); but now, an increasing awareness of the importance of gene therapy and genetically engineered cellular medicinal products.